Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases

Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02184039

Enrollment

12687

Registered

2014-07-09

Start date

2003-05-31

Completion date

Unknown

Last updated

2014-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* none

Exclusion criteria

* Hypersensitivity to meloxicam or to other NSAIDS * History of asthma, angioedema or urticaria secondary to NSAIDS * Pregnancy or lactation * Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure * Age below of 12 years.

Design outcomes

Primary

Measure	Time frame
Change in intensity of the symptoms measured with a four-point scale	Baseline, 30 and 90 days

Secondary

Measure	Time frame
Number of patients with adverse events	up to 90 days
Degree of satisfaction evaluated with a six point numerical rating scale	up to 90 days

Outcome results